Christine Kim: Development of hypoxia-activated prodrugs of second generation analogues of Bedaquiline for treatment of latent Tuberculosis

The main objective of my project is to develop and explore hypoxia activated prodrug (HAP) strategy to deliver the FDA approved agent bedaquiline and its analogues TBAJ-587 and TBAJ-876 selectively to hypoxic tubercular granuloma regions. Synthetic protocols of HAPs of these compounds are developed through exploring different synthetic routes.

This poster was uploaded for the SGS Research Showcase 2023.